peptide guide FAQ

File an Investigational New Drug (IND) application with the FDA if the study involves administering KPV to human subjects. The IND pathway requires preclinical safety data, manufacturing process documentation, and a detailed clinical protocol reviewed by an Institutional Review Board. For non-human research. Cell culture studies, animal models, or in vitro assays. IND filing is not required, but institutional biosafety and chemical safety approvals may apply depending on your facility. Purchase research-grade KPV with full analytical testing (HPLC, mass spectrometry, endotoxin testing) and retain batch records for protocol documentation. The peptide's legal status does not exempt it from research ethics oversight or institutional safety requirements.

Your physician must work with a licensed 503A or 503B compounding pharmacy that prepares patient-specific formulations under valid prescription. The prescription must document medical necessity and be issued within an established patient-physician relationship. Prescriptions issued via online questionnaires without synchronous consultation may not meet state medical board standards. Some states require additional documentation for off-label peptide prescriptions, particularly for compounds without any FDA-approved indication. If your physician is unfamiliar with peptide compounding regulations, recommend they consult with compounding pharmacies that specialize in peptide formulations and can verify state-specific compliance requirements.